Study wrapper · #343
Bremelanotide for Treatment of Female Hypoactive Sexual Desire.
Editor's note
A focused narrative review of bremelanotide (PT-141) for HSDD. It accurately conveys the mechanism (melanocortin-receptor agonism), the approved on-demand subcutaneous protocol, and that controlled trials reported improvements in desire, arousal and orgasm scores versus placebo. Two points temper it. First, as a non-systematic review it summarizes rather than weighs the evidence, and its closing framing ("promising") is more upbeat than the modest effect sizes in the pivotal trials warrant — the real-world gain was roughly half an additional satisfying event per month. Second, the abstract's mention of intranasal administration is outdated: the nasal formulation was discontinued after blood-pressure signals, and only the subcutaneous form is approved. The abstract's stated dosage reflects the regulatory label, not clinical advice from us. Treat this as a serviceable primer on the approved indication, cross-checked against the original RECONNECT data and safety review for balance.
Plain-language abstract
This review explains bremelanotide (PT-141) as an option for hypoactive sexual desire disorder (HSDD) — persistent, distressing low sexual desire — in women. It describes HSDD as arising from a mix of hormones, brain chemistry, and brain anatomy, which makes it complicated to address. Bremelanotide acts on melanocortin receptors and was approved by the FDA for this condition. The article notes it is given as an injection under the skin (1.75 mg into the abdomen or thigh) at least 45 minutes before sexual activity; it also mentions a nasal route, though in practice only the injectable form is approved. The authors report that studies found improvements in desire, arousal, and orgasm scores when the drug was used before sexual activity compared with placebo, and describe it as a promising approach. The abstract does not give the size of those improvements or list side effects, both of which are covered more fully in the original trials and safety reviews.